Phase 2a randomized, placebo-controlled study of anti–IL-33 in peanut allergy

BACKGROUND: IL-33, found in high levels in participants with allergic disorders, is thought to mediate allergic reactions. Etokimab, an anti–IL-33 biologic, has previously demonstrated a good safety profile and favorable pharmacodynamic properties in many clinical studies. METHODS: In this 6-week pl...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:JCI Insight
Egile Nagusiak: Chinthrajah, Sharon, Cao, Shu, Liu, Cherie, Lyu, Shu-Chen, Sindher, Sayantani B., Long, Andrew, Sampath, Vanitha, Petroni, Daniel, Londei, Marco, Nadeau, Kari C.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society for Clinical Investigation 2019
Gaiak:
Clinical Medicine
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6948865/
https://ncbi.nlm.nih.gov/pubmed/31723064
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.131347
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak